Answers are grounded in this paper and cite their sources.
Perioperative management of Wolff-Parkinson-White (WPW) syndrome patients undergoing high-risk surgeries presents significant challenges. Dexmedetomidine has been widely evaluated for its ability to increase the refractory period of cardiac action potentials in patients with pre-excitation syndromes, and it also shows promising results in maintaining hemodynamics and reducing the burden of arrhythmic complications. Different techniques and adjuvants have been used to manage pre-excitation syndromes and cardiac effects of dexmedetomidine make it a potential choice in such patients. However, further research is needed to fully understand its benefits and risks. We present the case of an asymptomatic, healthy 27-year-old patient with WPW syndrome who underwent donor nephrectomy, where dexmedetomidine was used perioperatively to maintain stable hemodynamics.
No takes yet. Share an insight, caveat, or question.
Muthukumar et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: